Evaluation of the 5‑fluorouracil plasma level in patients with colorectal cancer undergoing continuous infusion chemotherapy

  • Authors:
    • Yu Abe
    • Naoki Sakuyama
    • Tsuyoshi Sato
    • Kenji Kishine
    • Kiichi Nagayasu
    • Akinori Nakatani
    • Masayuki Kitajima
    • Tomoo Watanabe
    • Kazuhiko Nishimura
    • Takumi Ochiai
    • Isao Nagaoka
  • View Affiliations

  • Published online on: July 3, 2019     https://doi.org/10.3892/mco.2019.1893
  • Pages: 289-295
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

5‑Fluorouracil (5‑FU) dosing has traditionally been based on the body surface area (BSA) in colorectal cancer treatment. However, there is accumulating evidence that dosing based on BSA may be of limited use. The purpose of the present study was to evaluate the changes in 5‑FU plasma levels and tumor response as well as the severity of adverse events in patients with cancer treated with 5‑FU combined chemotherapy. The dosing amount of 5‑FU was determined based on the BSA. Blood samples were collected, and 5‑FU plasma levels in 15 patients with colorectal cancer were measured three times (0, 22 and 40 h before and after the start of infusion) during constant‑infusion of 5‑FU for 46 h by an immunoassay. 5‑FU plasma levels were significantly higher at 22 and 40 h compared with at 0 h (P<0.001), when all 15 patients were analyzed. Notably, the tumor response of the partial response/stable disease group showed significant increases in 5‑FU plasma levels at 40 h compared with at 22 h (P<0.01), while the progressive disease group showed no significant increase. In addition, the 5‑FU plasma level in the adverse event level of grade ≥2 was higher than that of grade <2 at 40 h after the start of infusion. Collectively, these observations indicated that during continuous infusion of 5‑FU, the 5‑FU plasma level increased significantly, and the tumor response (such as partial response, stable or progressive disease) may be influenced by the increase of 5‑FU plasma level from the start of infusion. Therefore, the 5‑FU plasma level may be a predictive factor for maximizing the tumor response and minimizing the risk of severe adverse events.

References

1 

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI

2 

Benson AB III, Venook AP, Cederquist L, Chan E, Chen YJ, Cooper HS, Deming D, Engstrom PF, Enzinger PC, Fichera A, et al: Colon cancer, version 1.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 15:370–398. 2017. View Article : Google Scholar : PubMed/NCBI

3 

Mayer RJ: Moving beyond fluorouracil for colorectal cancer. N Engl J Med. 343:963–964. 2000. View Article : Google Scholar : PubMed/NCBI

4 

de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 18:2938–2947. 2000. View Article : Google Scholar : PubMed/NCBI

5 

Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 343:905–914. 2000. View Article : Google Scholar : PubMed/NCBI

6 

Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol. 22:229–237. 2004. View Article : Google Scholar : PubMed/NCBI

7 

Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 351:337–345. 2004. View Article : Google Scholar : PubMed/NCBI

8 

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI

9 

Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, et al: Cetuximab for the treatment of colorectal cancer. N Engl J Med. 357:2040–2048. 2007. View Article : Google Scholar : PubMed/NCBI

10 

Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA and Benson AB III; Eastern Cooperative Oncology Group Study E3200, : Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 25:1539–1544. 2007. View Article : Google Scholar : PubMed/NCBI

11 

Wu M, Rivkin A and Pham T: Panitumumab: Human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer. Clin Ther. 30:14–30. 2008. View Article : Google Scholar : PubMed/NCBI

12 

Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, Andre T, Chan E, Lordick F, Punt CJ, et al: Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol. 28:4706–4713. 2010. View Article : Google Scholar : PubMed/NCBI

13 

Saam J, Critchfield GC, Hamilton SA, Roa BB, Wenstrup RJ and Kaldate RR: Body surface area-based dosing of 5-fluoruracil results in extensive interindividual variability in 5-fluorouracil exposure in colorectal cancer patients on FOLFOX regimens. Clin Colorectal Cancer. 10:203–206. 2011. View Article : Google Scholar : PubMed/NCBI

14 

Patel JN, O'Neil BH, Deal AM, Ibrahim JG, Sherrill GB, Olajide OA, Atluri PM, Inzerillo JJ, Chay CH, McLeod HL and Walko CM: A community-based multicenter trial of pharmacokinetically guided 5-fluorouracil dosing for personalized colorectal cancer therapy. Oncologist. 19:959–965. 2014. View Article : Google Scholar : PubMed/NCBI

15 

Saif MW, Choma A, Salamone SJ and Chu E: Pharmacokinetically guided dose adjustment of 5-fluorouracil: A rational approach to improving therapeutic outcomes. J Natl Cancer Inst. 101:1543–1552. 2009. View Article : Google Scholar : PubMed/NCBI

16 

Gamelin E, Boisdron-Celle M, Delva R, Regimbeau C, Cailleux PE, Alleaume C, Maillet ML, Goudier MJ, Sire M, Person-Joly MC, et al: Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: Results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. J Clin Oncol. 16:1470–1478. 1998. View Article : Google Scholar : PubMed/NCBI

17 

Ychou M, Duffour J, Kramar A, Debrigode C, Gourgou S, Bressolle F and Pinguet F: Individual 5-FU dose adaptation in metastatic colorectal cancer: Results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen. Cancer Chemother Pharmacol. 52:282–290. 2003. View Article : Google Scholar : PubMed/NCBI

18 

Kaldate RR, Haregewoin A, Grier CE, Hamilton SA and McLeod HL: Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6. Oncologist. 17:296–302. 2012. View Article : Google Scholar : PubMed/NCBI

19 

Capitain O, Asevoaia A, Boisdron-Celle M, Poirier AL, Morel A and Gamelin E: Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: A phase II, proof-of-concept study. Clin Colorectal Cancer. 11:263–267. 2012. View Article : Google Scholar : PubMed/NCBI

20 

Gamelin E, Delva R, Jacob J, Merrouche Y, Raoul JL, Pezet D, Dorval E, Piot G, Morel A and Boisdron-Celle M: Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: Results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol. 26:2099–2105. 2008. View Article : Google Scholar : PubMed/NCBI

21 

Cho J, Yoon J, Kim Y, Oh D, Kim SJ, Ahn J, Suh GY, Nam SJ and Mitchell SA: Linguistic validation of the US national cancer institute's patient-reported outcomes version of the common terminology criteria for adverse events in Korean. J Glob Oncol. 5:1–10. 2019. View Article : Google Scholar

22 

Watanabe T, Muro K, Ajioka Y, Hashiguchi Y, Ito Y, Saito Y, Hamaguchi T, Ishida H, Ishiguro M, Ishihara S, et al: Japanese society for cancer of the colon and rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol. 23:1–34. 2018. View Article : Google Scholar : PubMed/NCBI

23 

Correa GT, Bandeira GA, Cavalcanti BG, Santos FB, Rodrigues Neto JF, Guimaraes AL, Haikal DS and De Paula AM: Analysis of ECOG performance status in head and neck squamous cell carcinoma patients: Association with sociodemographical and clinical factors, and overall survival. Support Care Cancer. 20:2679–2685. 2012. View Article : Google Scholar : PubMed/NCBI

24 

Skierka AS and Michels KB: Ethical principles and placebo-controlled trials-interpretation and implementation of the Declaration of Helsinki's placebo paragraph in medical research. BMC Med Ethics. 19:242018. View Article : Google Scholar : PubMed/NCBI

25 

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI

26 

Ishiguro S: Pathological diagnosis of colorectal cancer according to Japanese classification of colorectal carcinoma. Nihon Rinsho. 69 (Suppl 3):S325–S329. 2011.(In Japanese).

27 

Pinedo HM and Peters GF: Fluorouracil: Biochemistry and pharmacology. J Clin Oncol. 6:1653–1664. 1988. View Article : Google Scholar : PubMed/NCBI

28 

Lu ZH, Zhang R and Diasio RB: Purification and characterization of dihydropyrimidine dehydrogenase from human liver. J Biol Chem. 267:17102–17109. 1992.PubMed/NCBI

29 

Diasio RB and Lu Z: Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy. J Clin Oncol. 12:2239–2242. 1994. View Article : Google Scholar : PubMed/NCBI

30 

Diasio RB and Johnson MR: Dihydropyrimidine dehydrogenase: Its role in 5-fluorouracil clinical toxicity and tumor resistance. Clin Cancer Res. 5:2672–2673. 1999.PubMed/NCBI

31 

Zahnd D, Aebi S, Rusterholz S, Fey MF and Borner MM: A randomized crossover trial assessing patient preference for two different types of portable infusion-pump devices. Ann Oncol. 10:727–729. 1999. View Article : Google Scholar : PubMed/NCBI

32 

Capdevila X, Macaire P, Aknin P, Dadure C, Bernard N and Lopez S: Patient-controlled perineural analgesia after ambulatory orthopedic surgery: A comparison of electronic versus elastomeric pumps. Anesth Analg. 96:414–417, table of contents. 2003. View Article : Google Scholar : PubMed/NCBI

33 

Ganapathy S, Amendola A, Lichfield R, Fowler PJ and Ling E: Elastomeric pumps for ambulatory patient controlled regional analgesia. Can J Anaesth. 47:897–902. 2000. View Article : Google Scholar : PubMed/NCBI

34 

Kaye T: Prolonged infusion times with disposable elastomeric infusion devices. Am J Hosp Pharm. 51:533–534. 1994.PubMed/NCBI

35 

Gamelin EC, Danquechin-Dorval EM, Dumesnil YF, Maillart PJ, Goudier MJ, Burtin PC, Delva RG, Lortholary AH, Gesta PH and Larra FG: Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer. 77:441–451. 1996. View Article : Google Scholar : PubMed/NCBI

36 

Blaschke M, Blumberg J, Wegner U, Nischwitz M, Ramadori G and Cameron S: Measurements of 5-FU plasma concentrations in patients with gastrointestinal cancer: 5-FU levels reflect the 5-FU dose applied. J Cancer Ther. 3:28–36. 2012. View Article : Google Scholar

Related Articles

Journal Cover

September 2019
Volume 11 Issue 3

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Abe, Y., Sakuyama, N., Sato, T., Kishine, K., Nagayasu, K., Nakatani, A. ... Nagaoka, I. (2019). Evaluation of the 5‑fluorouracil plasma level in patients with colorectal cancer undergoing continuous infusion chemotherapy. Molecular and Clinical Oncology, 11, 289-295. https://doi.org/10.3892/mco.2019.1893
MLA
Abe, Y., Sakuyama, N., Sato, T., Kishine, K., Nagayasu, K., Nakatani, A., Kitajima, M., Watanabe, T., Nishimura, K., Ochiai, T., Nagaoka, I."Evaluation of the 5‑fluorouracil plasma level in patients with colorectal cancer undergoing continuous infusion chemotherapy". Molecular and Clinical Oncology 11.3 (2019): 289-295.
Chicago
Abe, Y., Sakuyama, N., Sato, T., Kishine, K., Nagayasu, K., Nakatani, A., Kitajima, M., Watanabe, T., Nishimura, K., Ochiai, T., Nagaoka, I."Evaluation of the 5‑fluorouracil plasma level in patients with colorectal cancer undergoing continuous infusion chemotherapy". Molecular and Clinical Oncology 11, no. 3 (2019): 289-295. https://doi.org/10.3892/mco.2019.1893